
|Articles|September 1, 2006
Do lentiviral vectors hold the answer to glaucoma therapy?
Fort Lauderdale, FL-Investigators have shown for the first time in nonhuman primates that, using lentiviral vectors, it is possible to achieve good gene marker expression that is sustained and that does not cause inflammation or other side effects. The most important factor in this research with lentiviral vectors is the longevity of the expression in contrast to adenoviral vectors, according to Eric Poeschla, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR Surgical announces amendments to Alcon merger agreement, further delays deal
2
FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics
3
Five-year GALE study data announced
4
AAO 2025: The value of RGB imaging in OCT
5



















































.png)


